Check out our comprehensive educational activities here

Is there data to support routine use of FLT3 inhibitors in AML patients outside of a clinical trial?

Dr. Naval Daver discusses data supporting use of FLT3 inhibitors in patients with AML outside of a clinical trial, including adding midostaurin to standard chemotherapy.

Published on May 31, 2017 in Treatment

What FLT3 inhibitors are being evaluated in AML and what is the development status of these agents?

Join Dr. Naval Daver as he discusses the FLT3 inhibitors that are being evaluated in AML, including quizartinib, gilteritinib, and crenolanib.

Published on May 31, 2017 in Treatment

What are the latest updates on the IDH1 and IDH2 inhibitor studies?

Join Dr. Naval Daver as he reviews the latest data from studies of IDH1 and IDH2 inhibitors, which have shown promising activity in patients with AML.

Published on May 31, 2017 in Treatment

In the area of prognostic markers in AML, what do community providers need to know to be up-to-date?

Dr. Brian Druker explains what community providers need to know in order to best treat AML utilizing prognostic features in their patients.

Published on May 31, 2017 in Treatment

What are the latest updates on the Beat AML Master Trial?

Join Dr. Druker as he discusses the Beat AML Master Trial and how it aims to advance treatment for patients by better understanding genomics and driving mutations in these patients.

Published on May 31, 2017 in Treatment

Immunotherapy in AML: Monoclonal Antibodies

In this interview, Dr. Naval Daver provides insight into clinical trials using monoclonal antibodies to achieve complete remission in patients with AML.

Published on May 26, 2017 in Treatment in Clinical Trials